MANAGEMENT OF STEROID RESISTANT ULCERATIVE DISEASE INVOLUTION IS COMMON AMONG
2021; Gut Methods prolonged steroid use and side-effects. There is insufficient
steroid resistant UC has been highlighted – influential role of HCPs when patients choose treatments for
Conclusion options are exhausted. (4) Changes over time: there was an
effectiveness overall. (4) Changes over time: there was an
increase in willingness to try alternative treatments, and eventu-
ally surgery over time, in accordance with the severity and
duration of symptoms, and crucially, as medical treatment
options are exhausted.
Conclusion The importance of treatment efficacy and the
influential role of HCPs when patients choose treatments for
steroid resistant UC has been highlighted – with a willingness
to consider different treatments over time. Less value was
placed on side-effects and route of administration. This study
provides a qualitative perspective on patient preferences which
should be considered in practice guidelines and trial design.

Introduction Corticosteroids are a mainstay in the treatment
of moderately severe relapses of ulcerative colitis (UC), yet
almost 50% of patients do not respond fully, with the risk of
prolonged steroid use and side-effects. There is insufficient
evidence to inform optimum treatment choice for steroid
resistant disease. The aim of this study was to provide details of
current practice in the management of steroid resistant UC.
Methods A cross-sectional survey of Inflammatory Bowel Dis-
ease (IBD) healthcare professionals (HCPs) in the UK was con-
ducted online using the Qualtrics platform. HCPs were invited
to participate in the survey through professional networks:
British Society of Gastroenterology IBD section, Royal College
of Nursing IBD Nurses Network, and social media. Clinical
scenarios representing patients with moderately severe UC
with continuing symptoms (steroid resistant (SR)) and with
relapse after steroid dose reduction (steroid dependent (SD))
were included – both thiopurine treated (TP+) and naïve (TP-
). Data were analysed descriptively with chi-squared tests on outcomes of interest using R software.
Results 387 HCPs visited the survey; 47% (168 HCPs) con-
sented (68% medical; 30% nurses; median 7.5 years since
appointment) across all UK regions. Definitions of steroid
resistance varied: 68% indicating an incomplete response to
prednisolone 40 mg/day after 2 weeks and after 4 weeks in a
further 58%. Only 13% felt that SR and SD disease should be
treated identically.
Anti-TNF drugs would be most frequently offered in each
scenario (SR: TP+ 95%; TP- 87%; SD: TP+ 88%; TP- 74%)
with infliximab most frequently suggested; apart from SD TP-
patients flaring at prednisolone 5 mg/day. Admission for IV
steroids was offered more often for SR disease (32%) than
for SD (12%).
In SD scenarios, thiopurine treatment would be instigated in
TP- patients flaring at 25 mg prednisolone or 5 mg/day in
49% and in 70% respectively. Anti-TNF treatment would be
offered more frequently if patients are TP+ in both SR (TP+
81%; TP- 62% p=0.004) or SD patients and particularly for
those relapsing at 5 mg/day (Relapse at 25 mg/day: TP+ 78%
TP- 49%, p<0.001; Relapse at 5 mg/day TP+85% TP- 46%,
p<0.001). For both SR and SD disease, 43% and 58%
respectively felt that endoscopy is not warranted.
Conclusions There are important variations in practice in the
UK in how to define, treat and use endoscopy in steroid resistant UC. Such variations need to be understood as part of
initiatives to change practice - particularly to avoid excess ste-
roid use - and in trial design.

Introduction Paediatric Crohn’s disease (PCD) often presents
with a pan-enteric phenotype at diagnosis. However, its long-
term evolution in to adulthood, especially since the advent of
biological therapy, is not well characterised. Only few
studies have assessed this change, with conflicting results and
limited by short follow-up times. Our study aimed to evalu-
ate how the PCD phenotype evolves through childhood into
adult life.
Methods We performed a single-centre retrospective study of
PCD patients diagnosed ≤16 years of age, transitioned to an
adult gastroenterology unit with a minimum follow up of 2
years. Disease location and behaviour was characterised using
Paris and Montreal classification at diagnosis and follow-up
respectively. We assessed for evidence of disease extension or
involution as well as variables associated with complicated dis-
ease behaviour and surgery. Comparison of frequencies was
performed using Pearson’s chi-square test. Hazard ratios from
Cox proportional hazards models were used to quantify risk of
surgery and complicated disease behaviour.
Results 132 patients were included, transitioning to adult care
between 2002 and 2016. The median age at diagnosis was 13
(IQR 11–14) and median follow up 11 years. At diagnosis, 27
(20.4%) patients had complicated disease behaviour compared to 46 (34.9%) at follow up (p=0.0018). 83 (62.9%) patients had a ‘pan-enteric’ phenotype at diagnosis, however only 53 (66.3%) retained this phenotype at follow-up (p=0.0002). Disease extension was noted in 18.9% of patients and involution in 35.6% of patients, with upper GI disease noted in only 15.9% of patients at follow-up (p=0.0001). There was a high exposure to both thiopurines (91.7%) and biologics (63.6%), with a median time to starting treatment of 0 (IQR 0–1) and 5 (IQR 2–7) years for thiopurines and anti-TNF therapy respectively. The rate of exposure to biological therapy was similar in patients with disease involution (32/47, 68.1%) and disease extension (21/25, 84%). The cumulative probability (95% CI) of surgery was 0.05 (0.02, 0.11) at 1 year, 0.17 (0.11, 0.24) at 3 years and 0.22 (0.15, 0.30) at 5 years respectively. Overall, 56 (42.4%) patients had surgery at the end of follow-up. Neither disease location nor behaviour were associated with need for surgery.

Conclusions Changes in both disease location and behaviour were seen in our PCD cohort as they progressed to adult life. A significant proportion had disease involution, likely related to a high rate of exposure to biological therapy.

P99 ROUTINE IMAGING OF CROHN’S DISEASE WITH ULTRASOUND AND MR ENTEROGRAPHY: THE PATIENT PERSPECTIVE
Katie Devlin*, Gurinder Nandra, James Pilcher, Richard Pollok, Jaymin Harivadan Patel. St George’s University Hospital, London, UK
10.1136/gutjnl-2020-bsgcampus.174

Introduction Assess patient understanding, tolerance and preferences with regards to modern imaging techniques of small bowel Crohn’s disease.

Methods Consecutive paper-based questionnaires were obtained from patients referred for diagnosis, assessment or reassessment of Crohn’s disease with MR enterography (MRE) (n=50) and small bowel ultrasound (SBUS) (n=50) at a large teaching hospital. Analysis performed with SPSS as unpaired non-parametric data.

Results 66% (n=56/88) of patients were unsure which examination was more ‘accurate’. There was an inclination towards preferencing the examination that patient had attended for i.e. the SBUS cohort thought that SBUS was more accurate than MRE (18% versus 9%) whilst the MRE group favoured MRE over SBUS (33% versus 2%).

Free text responses regarding the cause of discomfort during MRE included: positioning (lying prone), claustrophobia and the volume of oral contrast. 94% (n=47) of MRE patients received oral contrast vs. 10% (n=5) of SBUS patients. Responses in the SBUS group related to probe pressure.

Regarding quality of information provided following the test, the mean score was 10 for SBUS patients versus 0 for MRE (0=not given opportunity to speak to someone, 10=indicating most satisfied with quality of information provided). Free text responses commented specifically on the ability to see and understand their disease with SBUS.

60% (n=29) of the SBUS cohort scored 10 for overall experience (median 10) versus 19% of the MRE group (median=8). Most participants would undergo the same examination again (96% and 100% of the SBUS and MRE cohorts respectively).

Abstract P99 Figure 1 Patient responses to ‘How uncomfortable was the examination?’ 1=Uncomfortable, 10=Comfortable

45% patients had experienced both MRE and SBUS at some point in their history. Of these, 68% (n=21) preferred SBUS, 16% (n=4) preferred MRE and 16% responded ‘either.’

Conclusions SBUS and MRE both demonstrate excellent sensitivity and specificity in the assessment of small bowel inflammation in Crohn’s disease. Either examination is suitable as a first-line investigation, although MRE is more sensitive than SBUS in diagnosing the extent of disease.³ This study demonstrates that SBUS is often better preferred by patients as a stand-alone test and compared with MRE. This is secondary to a combination of better patient comfort, the ability to immediately discuss findings with a radiologist following the examination and a perceived similar accuracy.

REFERENCES

P100 OUTCOMES OF A CLINICAL PSYCHOLOGY INTERVENTION IN A UK IBD SERVICE
Fiona Eldridge*, Konstantina Strongili, Miles Parkes, Tim Raine. Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
10.1136/gutjnl-2020-bsgcampus.175

Introduction Patients with IBD experience significant psychological distress. A variety of interventions to ameliorate this distress have been studied. However, to date no European study has assessed the impact on patients of a clinical psychologist embedded within the IBD team. Clinical psychology is uniquely characterised by its use of a patient/therapist collaborative formulation to guide and select from a variety of evidenced-based psychological therapeutic treatment options. Such an approach is likely to be particularly beneficial for patients with IBD who may present with a wide range of needs from adjustment at diagnosis to coping with symptoms, adhering to treatment protocols and managing an on-going relationship with a medical team.

Methods A novel clinical psychology service was established within an existing IBD service at a large UK tertiary centre. Patients were referred either by a gastroenterologist, IBD